Baroncelli Giampiero I, Bertelloni Silvano
Pediatric Unit I, Department of Obstetrics, Gynecology and Pediatrics, University Hospital, Pisa, Italy.
Horm Res Paediatr. 2014;82(5):290-302. doi: 10.1159/000365889. Epub 2014 Nov 6.
Bisphosphonates are widely used for the prevention and treatment of osteoporosis in adulthood. In the last years, bisphosphonates have been increasingly used in pediatric patients for the treatment of a growing number of disorders associated with osteoporosis, resistant hypercalcemia or heterotopic calcifications. The use of bisphosphonates in pediatric patients has been proven safe; however, the risk of potential severe consequences into adulthood should be kept in mind. Well-defined criteria for bisphosphonates treatment in pediatric patients are not specified, therefore an accurate selection of patients who could benefit from bisphosphonates is mandatory. A strict follow-up of pediatric patients receiving long-term bisphosphonate therapy is strongly recommended. The purpose of this mini review is to provide a summary of current knowledge on some main general aspects of the structure, mechanisms of action, pharmacokinetics, and bioavailability of bisphosphonates, and to focus on the latest advances of bisphosphonate treatment in pediatric patients. Particular attention has been paid to the common and potential adverse effects of bisphosphonate treatment, and some suggestions concerning the clinical approach and general measures for bisphosphonate treatment in pediatric patients are reported.
双膦酸盐广泛用于预防和治疗成人骨质疏松症。在过去几年中,双膦酸盐越来越多地用于儿科患者,以治疗越来越多与骨质疏松症、难治性高钙血症或异位钙化相关的疾病。双膦酸盐在儿科患者中的使用已被证明是安全的;然而,应牢记其在成年期可能产生严重后果的风险。目前尚未明确规定儿科患者双膦酸盐治疗的明确标准,因此必须准确选择可能从双膦酸盐治疗中获益的患者。强烈建议对接受长期双膦酸盐治疗的儿科患者进行严格随访。本综述的目的是总结关于双膦酸盐的结构、作用机制、药代动力学和生物利用度等一些主要一般方面的现有知识,并关注双膦酸盐治疗儿科患者的最新进展。特别关注了双膦酸盐治疗的常见和潜在不良反应,并报告了一些关于儿科患者双膦酸盐治疗的临床方法和一般措施的建议。